Cite
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
MLA
Diéras, Véronique, et al. “Veliparib with Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” Lancet Oncology, vol. 21, no. 10, Oct. 2020, pp. 1269–82. EBSCOhost, https://doi.org/10.1016/S1470-2045(20)30447-2.
APA
Diéras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., Jalving, M., Oprean, C., Palácová, M., Park, Y. H., Shparyk, Y., Yañez, E., Khandelwal, N., Kundu, M. G., Dudley, M., & Ratajczak, C. K. (2020). Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 21(10), 1269–1282. https://doi.org/10.1016/S1470-2045(20)30447-2
Chicago
Diéras, Véronique, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, et al. 2020. “Veliparib with Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” Lancet Oncology 21 (10): 1269–82. doi:10.1016/S1470-2045(20)30447-2.